Patents Examined by Kimberly Chong
  • Patent number: 10443055
    Abstract: Novel mIR-330 agents and their methods of use are provided. Methods of treating MYC-associated cancers are provided.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: October 15, 2019
    Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER
    Inventors: Pier Paolo Pandolfi, Assaf C. Bester, Yvonne Tay
  • Patent number: 10434178
    Abstract: This invention relates generally to in vivo delivery of active ingredient formulations. More particularly, this invention relates to formulations of active ingredients that further comprise an agent, methods of making such formulations, and methods of using the same.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: October 8, 2019
    Assignee: Adynxx Sub, Inc.
    Inventors: Julien Mamet, Scott Harris, George Miljanich, Rick Orr, William K. Schmidt, Tony Yaksh, David C. Yeomans
  • Patent number: 10436802
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy. Also provided are kits for detecting the amount of SMN protein in a sample of cerebrospinal fluid.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: October 8, 2019
    Assignee: Biogen MA Inc.
    Inventors: Frank Rigo, Katherine M. Bishop
  • Patent number: 10434187
    Abstract: Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector of replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: October 8, 2019
    Assignee: APHAVAX, INC.
    Inventors: Vernon McNeil Coffield, III, Kurt I. Kamrud, Jonathan F. Smith
  • Patent number: 10435691
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of filovirus infections. In particular, the present invention relates to a method of treating filovirus infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one oligonucleotide comprising the sequence as set forth in SEQ ID NO:1 to SEQ ID NO:15.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: October 8, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉET DE LA RECHERCHE MÉDICALE), UNIVERSITÉDE BORDEAUX
    Inventors: Samir Amrane, Jean-Louis Mergny, Amina Bedrat
  • Patent number: 10421962
    Abstract: Provided herein are double stranded nucleic acid molecules, compositions comprising same and methods of use thereof for the treatment of a subject wherein expression of DDIT4 is associated with the etiology or progression of a disease or disorder in the subject. The compounds are preferably chemically synthesized and modified dsRNA molecules.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: September 24, 2019
    Assignee: Quark Pharmaceuticals, Inc.
    Inventors: Elena Feinstein, Sharon Avkin-Nachum, Hagar Kalinski, Igor Mett
  • Patent number: 10421965
    Abstract: Described herein is a previously unknown function of XBP1 in controlling anti-tumor immunity. It is shown that inhibiting XBP1 in tumor-associated dendritic cells inhibits tumor growth and induces protective anti-tumor immune responses.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: September 24, 2019
    Assignee: Cornell University
    Inventors: Juan R. Cubillos-Ruiz, Laurie H. Glimcher
  • Patent number: 10421969
    Abstract: Certain disclosed oligomers induce exon skipping during processing of myostatin pre-mRNA. The oligomers may be in a vector or encoded by the vector. The vector is used for inducing exon skipping during processing of myostatin pre-mRNA. A therapeutically effective amount of the oligomer may be administered to a subject patient such that exon skipping during processing of myostatin pre-mRNA is induced. The administration to a subject may be used in order to increase or maintain muscle mass, or slowing degeneration of muscle mass in the subject. The administration to a subject may ameliorate muscle wasting conditions, such as muscular dystrophy. Examples of such muscular dystrophies which may be so treated include Becker's muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: September 24, 2019
    Assignee: Royal Holloway and Bedford New College
    Inventors: John George Dickson, Jagjeet Kaur Kang
  • Patent number: 10421966
    Abstract: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 214.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: September 24, 2019
    Assignee: The University of Western Australia
    Inventors: Stephen Donald Wilton, Sue Fletcher, Graham McClorey
  • Patent number: 10421989
    Abstract: We provide isolated TPP and preQ1 class II riboswitches which are labelled for FRET studies of ribosome function. The riboswitches may be used in assays to determine riboswitch function, and to test the activity of compounds in modulating riboswitch function.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: September 24, 2019
    Assignees: CORNELL UNIVERSITY, UNIVERSITY OF INNSBRUCK
    Inventors: Scott Blanchard, Roger Altman, Marie F. Souliere, Ronald Micura, Andrea Haller
  • Patent number: 10407681
    Abstract: The present disclosure provides compositions and methods utilizing double strand ribonucleic acid (dsRNA) to control parasitic nematodes, including Pratylenchus penetrans. More particularly, the present invention relates to several specific synthetic dsRNAs that induce RNA interference (RNAi) in the target nematodes and methods of delivering the dsRNAs to them, such as allowing feeding on plants containing the dsRNAs.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: September 10, 2019
    Assignees: The United States of America, as represented by The Secretary of Agriculture, Virginia Tech Intellectual Properties, Inc.
    Inventors: Kathryn K. Kamo, Paulo C. R. Vieira, Jonathan D. Eisenback
  • Patent number: 10407680
    Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of Tau mRNA in a cell or animal, and in certain instances reducing the amount of Tau protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include loss of memory, loss of motor function, and increase in the number and/or volume of neurofibrillary inclusions. Such neurodegenerative diseases include tauopathies, Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy (PSP), Chronic Traumatic Encephalopathy (CTE), Corticobasal Ganglionic Degeneration (CBD), Epilepsy, and Dravet's Syndrome.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: September 10, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Holly Kordasiewicz
  • Patent number: 10398784
    Abstract: Polyvalent nanoconjugates address the critical challenges in therapeutic use. The single-entity, targeted therapeutic is able to cross the blood-brain barrier (BBB) and is thus effective in the treatment of central nervous system (CNS) disorders. Further, despite the tremendously high cellular uptake of nanoconjugates, they exhibit no toxicity in the cell types tested thus far. This property is critical for therapeutic agent delivery applications for reducing off-target effects.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: September 3, 2019
    Assignee: NORTHWESTERN UNIVERITY
    Inventors: Chad A. Mirkin, Caroline H. Ko, David A. Giljohann, Janina Luciano, Samuel A. Jensen, Alexander Stegh
  • Patent number: 10391166
    Abstract: The invention provides a method of treating a microbial infection in a subject and a method of improving an immune system response in a subject against a disease, condition, infection, or virus thereof, by administering an effective amount of a nucleoside, short oligonucleotide compound or an analog thereof, or a pharmaceutically acceptable salt, racemate, enantiomer, diastereomer, geometric isomer, or tautomer thereof. In addition, the invention provides methods for treating or preventing a viral infection, bacterial infection, parasitic infection, or fungal infection in a subject (such as, a human). The compounds of the invention include, for example, di-, and trinucleotide compounds as provided herein. The compounds of the invention are useful for different therapeutic applications including, such as, prophylactics and therapeutics. The invention also provides design and synthesis of a compound that is useful for various therapeutic applications as mentioned herein.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: August 27, 2019
    Assignee: SPRING BREAK PHARMACEUTICALS, INC.
    Inventor: Radhakrishnan P. Iyer
  • Patent number: 10385341
    Abstract: Disclosed herein are antisense compounds and methods for decreasing SOD-1 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate SOD-1 associated diseases, disorders, and conditions. Such SOD-1 associated diseases include amyotrophic sclerosis (ALS).
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: August 20, 2019
    Assignee: Biogen MA Inc.
    Inventor: Eric E. Swayze
  • Patent number: 10378018
    Abstract: The present invention is directed towards an artificial RNA nanostructure comprising multiple external strands of RNA, each external strand comprising about 40-50 nucleotides; one internal strand of RNA comprising more than about 50 nucleotides; the internal strands and external strands assembled to form a triangle nanostructure, a square nanostructure, or a polygon nanostructure and a pRNA three-way junction (3WJ) motif at each vertex of the nanostructure. Such nanostructure can be provided in a composition together with an adjuvant for use in inducing the production of high affinity neutralizing antibodies or inhibitory antibodies, inducing the production of cytokines, inducing an immune response in a subject, or a combination thereof.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: August 13, 2019
    Assignee: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventors: Peixuan Guo, Hui Li, Emil Khisamutdinov, Daniel Jasinski
  • Patent number: 10369167
    Abstract: An RNA composition comprising an RNA aptamer and an shRNA molecule and/or an miRNA molecule are provided. The RNA composition may include an aptamer component that binds an enzymatic protein within a target cell and an shRNA and/or an miRNA component that facilitates trafficking of the aptamer within the target cell, such as, trafficking from the nucleus into the cytoplasm. The RNA aptamer and the shRNA and/or the miRNA component of the composition can be a fusion or independent molecules.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: August 6, 2019
    Assignee: CITY OF HOPE
    Inventors: Ka Ming Pang, John J. Rossi
  • Patent number: 10370661
    Abstract: Materials and methods for regulating gene expression using nanoparticles functionalized with antisense oligonucleotides are provided.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: August 6, 2019
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Chad A. Mirkin, Nathaniel L. Rosi, C. Shad Thaxton, David A. Giljohann
  • Patent number: 10370663
    Abstract: A method of producing nanovesicles comprising an oligonucleotide inhibitor to an oncogene or a proto-oncogene or the gene product thereof, said method comprises a) introducing a DNA sequence encoding an oligonucleotide capable of inhibiting a human oncogenic or proto-oncogenic transcription factor, into a mammalian cell; b) allowing the cell to express said inhibitor oligonucleotide; and c) obtaining nanovesicles containing said inhibitor oligonucleotide from said cell. Nanovesicles produced by the claimed method can be effectively and specifically targeted to e.g. cancer cells to deliver the inhibitor oligonucleotide.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: August 6, 2019
    Assignee: Codiak BioSciences, Inc.
    Inventors: Jan Lötvall, Jonas Andrej Nilsson
  • Patent number: 10357509
    Abstract: The present disclosure relates to compositions and methods for treating cancers using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (IGF-1R). The AS may be administered to the patients systemically, or may be used to produce an autologous cancer cell vaccine. In embodiments, the AS are provided in an implantable irradiated biodiffusion chamber comprising tumor cells and an effective amount of the AS. The chambers are irradiated and implanted in the abdomen of subjects and stimulate an immune response that attacks tumors distally. The compositions and methods disclosed herein may be used to treat many different kinds of cancer, for example glioblastoma.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: July 23, 2019
    Assignee: Thomas Jefferson University
    Inventors: David W. Andrews, Douglas C. Hooper